Use of Intravitreal Bevacizumab in Eyes With Choroidal Neovascularization Secondary to Angioid Streaks

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE3

Study Classification

INTERVENTIONAL

Study Start Date

2005-11-30

Study Completion Date

2006-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Intravitreal Bevacizumab is an effective treatment for choroidal neovascularization secondary to Angioid Streaks

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Bevacizumab for Inflammatory Neovascular Membranes

NCT00407121

Vogt Koyanagi Harada Disease Serpiginous Choroiditis Multifocal Choroiditis

WITHDRAWN PHASE3

Efficacy of Retreatments With Intravitreal Bevacizumab

NCT00406744

TERMINATED PHASE3

Efficacy and Safety of Intravitreal Bevacizumab in the Treatment of Choroidal Neovascular Membranes Associated to High Myopia

NCT00967850

Myopia Choroidal Neovascularization

COMPLETED PHASE3

Intravitreal Bevacizumab for Choridal Neovascularization Secondary to Age-Related Macular Degeneration

NCT00556348

Age Related Macular Degeneration

COMPLETED PHASE4

Effect of Intravitreal Bevacizumab on Non -Age-Related Macular Degeneration (AMD) Related Choroidal Neovascularization (CNV)

NCT00370786

Choroidal Neovascularization

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A consecutive case series of patients with angioid streaks that developed subfoveal choroidal neovascularization were treated with a primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally. All patients were evaluated with BCVA at 1, 2 , 4 and 12 weeks and OCT and fluoresceine angiography at month 1 and 3. (Patients will be follow 6 months)

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Angioid Streaks Choroidal Neovascularization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Intravitreal Bevacizumab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Angioid Streaks
* Choroidal neovascularization associated
* Untreated patients or patients treated once with PDT

Exclusion Criteria

* Ocular surgery excepting uncomplicated phacoemulsification
* Glaucoma or any other ocular pathology

Eligible Sex

ALL

Accepts Healthy Volunteers

No